icon
icon
icon
icon
Upgrade
Upgrade

News /

Articles /

MMM Earnings Preview: Margins and growth in focus

Jay's InsightMonday, Oct 21, 2024 1:28 pm ET
2min read

3M (MMM) is set to release its Q3 2024 earnings report pre-market on Tuesday, October 22. Analysts expect earnings per share (EPS) of $1.90, with a high estimate of $2.00 and a low of $1.78, reflecting a slight 1.7% upward revision over the last 30 days. Revenue is anticipated to come in at $6.06 billion. For the full year, 3M’s EPS is projected at $7.26, and full-year revenue is estimated at $23.62 billion. Investors are watching closely for how 3M performs in light of a forecasted earnings move of +/- 3.9% and a consensus "Buy" rating, with an average price target of $141.

3M reaffirmed its full-year guidance on September 12, maintaining its forecast for EPS between $7.00 and $7.30 and organic revenue growth of 0-2%. This has positioned the company to report organic sales growth within the middle of that range for the remainder of FY24. Key metrics to watch include the company's organic growth rate and margin improvements, both of which have been critical focal points since CEO Bill Brown took the helm earlier this year. Analysts have been especially impressed with Brown's focus on restructuring, which has begun yielding positive results.

Despite these positive developments, 3M still faces several challenges, including the ongoing weakness in consumer spending, which has affected segments such as automotive aftermarket, home improvement, and packaging. Analysts expect the company's Consumer segment to continue struggling in Q3. Conversely, its Transportation & Electronics and Safety & Industrial divisions are expected to perform better, with mid-single-digit growth anticipated in key areas like automotive OEM and industrial adhesives.

Mizuho recently raised its price target on 3M to $146, reflecting optimism about the company’s ongoing restructuring and the potential for continued margin improvement. However, Mizuho remains neutral on the stock, noting that further upside would require 3M to demonstrate sustained GDP+ growth—a challenge given the company’s historical underperformance relative to GDP growth. Morgan Stanley is less optimistic, issuing an Underweight rating with a price target of $125, citing concerns over weakening consumer spending and the company's recent re-rating.

3M's profitability in Q3 is likely to be a key focus for analysts and investors. The company has made strides in improving its margins, benefiting from restructuring and cost-cutting efforts. However, with a backdrop of global macroeconomic uncertainty and rising operational costs, maintaining these gains will be critical to the company's longer-term success. In the previous quarter, 3M’s adjusted EBITDA expanded by 430 basis points, contributing to a 39% year-over-year rise in its adjusted EPS.

3M delivered a strong performance in Q2 2024 under its new CEO, William Brown, who took the reins in May. Brown's leadership has been well-received, as evidenced by a double-digit earnings beat and a solid 1.2% year-over-year growth in organic revenue. The company's restructuring efforts, which included streamlining its operations and shifting to a global business unit structure, have already shown positive results. In Q2, 3M’s adjusted EPS from continuing operations surged 39% to $1.93, reflecting the impact of these changes and setting an optimistic tone for the future. As a result, 3M raised the low end of its adjusted EPS forecast for FY24 to $7.00-7.30, up from $6.80-7.30.

Growth was primarily driven by the Transportation & Electronics segment, which posted a 3.3% organic growth. Electronics showed a particularly strong performance, with a low-double-digit organic increase, highlighting improving demand in consumer electronics. 3M’s auto OEM business also posted nearly 5% growth in Q2, sustaining momentum from Q1. However, not all segments fared as well; the Safety & Industrial division saw only modest growth of 1.1%, while the Consumer segment experienced a 1.4% decline due to weak discretionary spending, which 3M expects to persist throughout the year.

Despite some challenges, including a cautious end-market environment and a $10.3 billion settlement related to PFAS levels, there is optimism surrounding 3M’s restructuring efforts and its early success under Brown's leadership. The leaner company has shown resilience in a tough global economy, and with continued focus on cost structure improvements and organic growth, analysts are increasingly bullish on the company's long-term prospects. Deutsche Bank has upgraded the stock to a Buy, citing potential upside of 18% and targeting a price of $150.

Overall, investors will be closely watching 3M's Q3 earnings report for signs of further margin improvements and any updates on the company's organic growth trajectory. While there is optimism surrounding the company’s restructuring efforts, challenges like weak consumer demand and ongoing legal liabilities will need to be addressed in order to sustain the stock's recent momentum.

Comments
User avatar and name identifying the post author
Straight_Turnip7056
05/16
ALTBG is like a gambler in a Bitcoin casino, betting big on a volatile market. Their stock's rollercoaster ride shows the risks of relying on Bitcoin's price swings. With all that debt and potential dilution, they're rolling the dice. If Bitcoin hits, they win big; if not, they might be left with a losing hand. It's a high-stakes game, and only time will tell if they've got the winning hand or a bust.
0
Reply
User avatar and name identifying the post author
istockusername
05/16
@Straight_Turnip7056 Yikes, that's a lot of debt.
0
Reply
User avatar and name identifying the post author
Connect_Corner_5266
05/16
@Straight_Turnip7056 True, it's a high-risk play.
0
Reply
User avatar and name identifying the post author
TheosophOracle
05/16
Damn!!🚀 BTC stock went full bull as tools from Premium benefits. Cashed out $457 gains!
0
Reply
User avatar and name identifying the post author
gaudspd
12 hour ago
Holy!the block option data in BTC stock saved me much money!
0
Reply
User avatar and name identifying the post author
CrisCathPod
05/15
Gotta diversify beyond GBM, NWBO. More pipelines!
0
Reply
User avatar and name identifying the post author
Relevations
05/15
Betting on immunotherapy is always dicey. Roll the dice.
0
Reply
User avatar and name identifying the post author
Artistic_Studio2784
05/15
NWBO is the ultimate Hail Mary pass. Only throw if you've got nothing to lose and everything to gain.
0
Reply
User avatar and name identifying the post author
maximalsimplicity
05/15
Sawston facility is the unsung hero here. GMP compliance is the difference between boom and bust.
0
Reply
User avatar and name identifying the post author
SeriousTsuki
05/15
NWBO's pipeline is like a lottery ticket. Buy with caution and a long breath. 🚀
0
Reply
User avatar and name identifying the post author
Arturs727
05/15
Burn rate vs. timeline is the tightrope walk. One misstep and it's curtains. Who's got the patience?
0
Reply
User avatar and name identifying the post author
Hamlerhead
05/15
NWBO's pipeline beyond GBM is like finding gold in a mine. Solid tumors could mean solid gains.
0
Reply
User avatar and name identifying the post author
Certain-Dragonfly-22
05/15
$NWBO might need a lifeline soon. Watch funding moves.
0
Reply
User avatar and name identifying the post author
jvdr999
05/15
DCVax-L's data looks solid, but regulatory hurdles are the Great Wall of China. Who's ready for the marathon?
0
Reply
User avatar and name identifying the post author
Doxfinity
05/15
DCVax-L could moon if approved. Eyes on UK.
0
Reply
User avatar and name identifying the post author
Overlord1317
05/15
Combo therapies might be the secret sauce. Keep an eye on those trials for hidden gems.
0
Reply
User avatar and name identifying the post author
Harpnut
05/15
Risky play here, but potential's huge. Long-term hold.
0
Reply
User avatar and name identifying the post author
Really_Schruted_It
05/15
Risky business, but if NWBO hits, we're talking life-changing. Not for the faint-hearted!
0
Reply
User avatar and name identifying the post author
Silgro94
05/15
Gotta love the biotech rollercoaster. NWBO's ride is particularly bumpy but potentially moon-worthy.
0
Reply
User avatar and name identifying the post author
ServentOfReason
05/15
Market cap is a steal if DCVax-L delivers. Betting on NWBO is like backing a dark horse race winner.
0
Reply
User avatar and name identifying the post author
Gnurx
05/15
@ServentOfReason What's your target entry point?
0
Reply
User avatar and name identifying the post author
Thanhansi-thankamato
05/15
@ServentOfReason Totally agree, NWBO's undervalued.
0
Reply
User avatar and name identifying the post author
StovetopAtol4
15 hour ago
"Talk about a budget bill on a collision course with an iceberg! Johnson’s 'Titanic' of a bill is set to sail through the House, but will it survive the Senate’s ice floes? With deadlines looming and lawmakers bickering like Jack and Rose over a lifeboat, this fiscal adventure might just go down in history—literally. Let’s hope they don’t need a 'Rosebud' moment when it all sinks.
0
Reply
User avatar and name identifying the post author
jabnabbar
14 hour ago
@StovetopAtol4 If this budget bill is the Titanic, then the Senate must be the iceberg. But hey, maybe they'll pull an Elon and make it a Mars budget—lots of room for fiscal growth, but a long way to go before splashdown.
0
Reply
User avatar and name identifying the post author
highrollerr90
15 hour ago
Holy!The TSLA stock was in an easy trading mode with Premium tools, and I made $108 from it!
0
Reply
User avatar and name identifying the post author
Square_Net_7271
15 hour ago
@highrollerr90 How long were you holding TSLA, and what's your plan with the gains?
0
Reply
User avatar and name identifying the post author
wangaa
5 min ago

16:50

0
Reply
User avatar and name identifying the post author
wangaa
46 min ago

see see

0
Reply
User avatar and name identifying the post author
wangaa
51 min ago

how

0
Reply
User avatar and name identifying the post author
wangaa
1 hour ago

see it

0
Reply
User avatar and name identifying the post author
wangaa
2 hour ago

let me see

0
Reply
User avatar and name identifying the post author
wangaa
2 hour ago

let me see

0
Reply
User avatar and name identifying the post author
Zurkarak
2 hour ago
@wangaa Cool
0
Reply
User avatar and name identifying the post author
ticklerbgs
04/22
OMG!The WFC stock was in a clear trend, and I made $199 from it!
0
Reply
User avatar and name identifying the post author
wangaa
2 hour ago
@ticklerbgs

OMG!

0
Reply
User avatar and name identifying the post author
FreeIcecreamAfterDin
37 min ago
@wangaa K boss
0
Reply
User avatar and name identifying the post author
StephCurryInTheHouse
04/24
Uniper's Q1 hit hard, but long-term vision still intact. Renewables are the future, but they need to fix supply chain mess.
0
Reply
User avatar and name identifying the post author
GarlicBreadDatabase
04/24
EU asset sales could free up capital. Silver lining?
0
Reply
User avatar and name identifying the post author
NRG1788
04/24
Holding $UNPR for long term, eyes on renewables.
0
Reply
User avatar and name identifying the post author
qw1ns
04/24
Diversify or die trying—Uniper's pivot to renewables is smart, but EU asset sales could hurt. Risky road ahead.
0
Reply
User avatar and name identifying the post author
coinfanking
04/24
$UNPR might be a value play post-Q1 fallout. High risk, high reward. Not adding to my portfolio yet.
0
Reply
User avatar and name identifying the post author
Crazy-Ad-7869
04/24
@coinfanking How long you planning to hold $UNPR if you decide to buy?
0
Reply
User avatar and name identifying the post author
foureyedgrrl
04/24
Uniper's hedging strategy looks shaky, folks. 🤔
0
Reply
User avatar and name identifying the post author
GME_Butt_Stallion
04/24
@foureyedgrrl Hedging's tough when prices drop.
0
Reply
User avatar and name identifying the post author
SnowySalesman
04/24
Diversify beyond Russian gas, Uniper. Risky business
0
Reply
User avatar and name identifying the post author
deepvalueresearch
04/24
@SnowySalesman True, Uniper's Russia gamble risky.
0
Reply
User avatar and name identifying the post author
Dynasty__93
04/24
Uniper's Q1 loss feels like a speed bump on a highway to renewables. Long-term vision or time to bail?
0
Reply
User avatar and name identifying the post author
styletrick
04/24
@Dynasty__93 What's your take on Uniper's long-term potential?
0
Reply
User avatar and name identifying the post author
vivifcgb
04/24
Market already priced in the pain. Investors skeptical but not bearish. Waiting for Uniper's next move. 🤔
0
Reply
User avatar and name identifying the post author
HJForsythe
04/24
Geopolitical risks are a major overhang. 🤷♂️
0
Reply
User avatar and name identifying the post author
vannucker
04/24
Lower commodity prices hit margins hard. Ouch!
0
Reply
User avatar and name identifying the post author
FreeIcecreamAfterDin
04/24
@vannucker True, commodity price swings hurt.
0
Reply
User avatar and name identifying the post author
Mahh_ko
04/24
Damn!!the block option data in AAPL stock saved me much money!
0
Reply
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.